ArticleSurgery today2017
The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer cases.
Article in Surgery today, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 52 citations in OpenAlex.
- Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer.Technology in cancer research & treatment · 2018Trial
- Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM.Journal of gastrointestinal oncology · 2026Article
- Significance of Serum Tumor Markers in Esophageal and Gastric Cancers: A Systematic Literature Review.Annals of gastroenterological surgery · 2026Review
- miR-129 as a Molecular Biomarker in Gastric Cancer and Its Association with Neurodegenerative and Vascular Pathology.Life (Basel, Switzerland) · 2025Article
- Extensive methylation analysis of circulating tumor DNA in plasma of patients with gastric cancer.Scientific reports · 2024Article
- In Pursuit of Novel Markers: Unraveling the Potential of miR-106, CEA and CA 19-9 in Gastric Adenocarcinoma Diagnosis and Staging.International journal of molecular sciences · 2024Article
- Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.British journal of cancer · 2024Observational
- Simultaneous Assay of CA 72-4, CA 19-9, CEA and CA 125 in Biological Samples Using Needle Three-Dimensional Stochastic Microsensors.Sensors (Basel, Switzerland) · 2023Article
- Prognostic significance of serum tumor marker normalization in the perioperative period for patients with advanced gastric cancer.Annals of translational medicine · 2022Article
- The Modified Glasgow Prognostic Score Predicts Survival in Gastric Cancer Patients with Normal CEA and CA19-9.Canadian journal of gastroenterology & hepatology · 2022Article
- Association of multiple tumor markers with newly diagnosed gastric cancer patients: a retrospective study.PeerJ · 2022Article
- Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.Surgery today · 2021Article
- Exosomal Protease Cargo as Prognostic Biomarker in Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy.BMC cancer · 2021Article
- Clinical importance of serum CEA and CA-19-9 levels in oesophagogastric junction adenocarcinomas.Przeglad gastroenterologiczny · 2021Article
- CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer.Journal of clinical medicine · 2020Review
- Article
- E-Cadherin Protein as a Potential Marker for Gastric Cancer and Its Association withReports of biochemistry & molecular biology · 2019Article
- Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer.World journal of gastrointestinal oncology · 2019Article
- The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer.Surgery today · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 are the most commonly used tumor markers in gastric cancer, the differences in the characteristics of these two markers remain unclear, because most previous studies have included many patients who were positive for both markers.
methodsWe analyzed the available data on 1050 patients with gastric cancer who underwent R0 resection. The background characteristics and recurrence-free survivals (RFS) were compared between the single-positive patients for CEA or CA 19-9 and double-negative patients.
resultsAmong these 1050 patients, 86 patients (8.2 %) were positive for CEA only, 77 patients (7.3 %) were positive for CA 19-9 only, and 867 patients (82.6 %) were double negative for both markers. Patients who were elderly, male and had a differentiated histology were more commonly observed in the CEA-positive group than in the double-negative group (P = 0.004, P = 0.009, and P = 0.001). The patients who were positive for either CEA or CA 19-9 had a significantly worse RFS than the patients who were negative for both (P < 0.001 and P < 0.001). The most frequent site of recurrence was the liver (9.3 %) in the CEA-positive group and the peritoneum (11.7 %) in the CA 19-9-positive group.
conclusionAge, sex, and histological type were thus found to be associated with CEA positivity. CEA is, therefore, considered to be a sensitive marker for liver recurrence, while CA 19-9 is a sensitive marker for peritoneal recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.